12:@0.491762:0.959891:0.508561:0.959891:0.508561:0.943626:0.491762:0.943626:0.008399:0.008399
百靈佳殷格翰:@0.449603:0.047478:0.550396:0.047478:0.550396:0.035100:0.449603:0.035100:0.016799:0.016799:0.016799:0.016799:0.016799:0.016799
`:@0.087542:0.203439:0.018982:0.203439:0.018982:0.192608:0.087542:0.192608:-0.106524
`:@0.197741:0.203439:0.091217:0.203439:0.091217:0.192608:0.197741:0.192608:-0.106524
! ! ! ! ! !:@0.201428:0.203439:0.208777:0.203439:0.208777:0.192608:0.201428:0.192608:0.007350:-0.007350:0.007350:-0.007350:0.007350:-0.007350:0.007350:-0.007350:0.007350:-0.007350:0.007350
`:@0.128095:0.216436:0.062126:0.216436:0.062126:0.205605:0.128095:0.205605:-0.065969
`:@0.197739:0.216436:0.131770:0.216436:0.131770:0.205605:0.197739:0.205605:-0.065969
! !:@0.201428:0.216436:0.208777:0.216436:0.208777:0.205605:0.201428:0.205605:0.007350:-0.007350:0.007350
`:@0.569522:0.179012:0.477447:0.179012:0.477447:0.168181:0.569522:0.168181:-0.092075
`:@0.665272:0.179012:0.573197:0.179012:0.573197:0.168181:0.665272:0.168181:-0.092075
!:@0.668960:0.179012:0.676310:0.179012:0.676310:0.168181:0.668960:0.168181:0.007350
`:@0.569522:0.192009:0.488472:0.192009:0.488472:0.181178:0.569522:0.181178:-0.081051
`:@0.654248:0.192009:0.573197:0.192009:0.573197:0.181178:0.654248:0.181178:-0.081051
`:@0.583333:0.225430:0.513483:0.225430:0.513483:0.214599:0.583333:0.214599:-0.069850
`:@0.656857:0.225430:0.587008:0.225430:0.587008:0.214599:0.656857:0.214599:-0.069850
!:@0.660546:0.225430:0.667895:0.225430:0.667895:0.214599:0.660546:0.214599:0.007350
`:@0.583333:0.238428:0.511322:0.238428:0.511322:0.227597:0.583333:0.227597:-0.072011
`:@0.659018:0.238428:0.587008:0.238428:0.587008:0.227597:0.659018:0.227597:-0.072011
`:@0.861904:0.247299:0.809105:0.247299:0.809105:0.236468:0.861904:0.236468:-0.052799
`:@0.918378:0.247299:0.865579:0.247299:0.865579:0.236468:0.918378:0.236468:-0.052799
!:@0.922066:0.247299:0.929416:0.247299:0.929416:0.236468:0.922066:0.236468:0.007350
`:@0.861904:0.260296:0.810311:0.260296:0.810311:0.249465:0.861904:0.249465:-0.051594
`:@0.917173:0.260296:0.865579:0.260296:0.865579:0.249465:0.917173:0.249465:-0.051594
!:@0.904777:0.859717:0.912126:0.859717:0.912126:0.848886:0.904777:0.848886:0.007350
!:@0.533221:0.547172:0.546661:0.547172:0.546661:0.527367:0.533221:0.527367:0.013439
    本公司的「無國界研究」:@0.071429:0.460121:0.325050:0.460121:0.325050:0.446505:0.071429:0.446505:0.012288:0.012288:0.009239:0.004398:0.019828:0.019828:0.019828:0.018479:0.019828:0.019828:0.019828:0.019828:0.019828:0.019828:0.018479
（Research Beyond Borders）:@0.071429:0.483949:0.325001:0.483949:0.325001:0.470333:0.071429:0.470333:0.018479:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.011292:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.011294:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.009239:0.018479
設立一個計畫，與外部合作夥:@0.071429:0.506851:0.325069:0.506851:0.325069:0.493235:0.071429:0.493235:0.019698:0.019698:0.019698:0.019698:0.019698:0.018479:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.018479
伴合作在核心研究治療領域的:@0.071429:0.529753:0.324958:0.529753:0.324958:0.516137:0.071429:0.516137:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.018479
內部和外部探索新興的科學方:@0.071429:0.552655:0.324958:0.552655:0.324958:0.539039:0.071429:0.539039:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.018479
法與技術。:@0.071429:0.575557:0.163823:0.575557:0.163823:0.561941:0.071429:0.561941:0.018479:0.018479:0.018479:0.018479:0.018479
   百靈佳殷格翰以改善高醫療:@0.071429:0.598459:0.325001:0.598459:0.325001:0.584843:0.071429:0.584843:0.010609:0.010609:0.010609:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
需求患者的生活品質為目標，:@0.071429:0.621361:0.325069:0.621361:0.325069:0.607745:0.071429:0.607745:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.018479:0.018479
致力於研發新一代具有開創性:@0.071429:0.644263:0.324958:0.644263:0.324958:0.630647:0.071429:0.630647:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.018479
的藥品。「導致疾病途徑的新:@0.071429:0.667166:0.324958:0.667166:0.324958:0.653550:0.071429:0.653550:0.019809:0.019809:0.018479:0.018479:0.019809:0.019809:0.019809:0.019809:0.019809:0.019809:0.019809:0.019809:0.018479
觀點對找出未來突破性的藥物:@0.071429:0.690068:0.324958:0.690068:0.324958:0.676452:0.071429:0.676452:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.018479
極其重要。」伍德說。「創新:@0.071429:0.712970:0.324958:0.712970:0.324958:0.699354:0.071429:0.699354:0.020142:0.020142:0.020142:0.018479:0.018479:0.020142:0.020142:0.020142:0.018479:0.018479:0.020142:0.020142:0.018479
與培 養敏銳的 洞察力 對激發:@0.071429:0.735872:0.325060:0.735872:0.325060:0.722256:0.071429:0.722256:0.021380:0.018479:0.002892:0.021380:0.021380:0.021380:0.018479:0.002892:0.021380:0.021380:0.018479:0.002892:0.021380:0.021380:0.018479
『研發藥物』精神極為重要。」:@0.071429:0.758774:0.325001:0.758774:0.325001:0.745158:0.071429:0.745158:0.018479:0.018479:0.018479:0.018479:0.018479:0.015912:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.015914:0.018479
        一旦找出一個新藥的目:@0.071429:0.781676:0.324962:0.781676:0.324962:0.768060:0.071429:0.768060:0.009239:0.003049:0.009239:0.003049:0.009239:0.003049:0.009239:0.005011:0.020438:0.020438:0.020438:0.020438:0.020438:0.020438:0.020438:0.020438:0.020438:0.018479
標，研究員便會決定最能達到:@0.071429:0.804578:0.325069:0.804578:0.325069:0.790962:0.071429:0.790962:0.018479:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.018479
治療目的的處理方法。「我們:@0.071429:0.827480:0.324956:0.827480:0.324956:0.813864:0.071429:0.813864:0.019809:0.019809:0.019809:0.019809:0.019809:0.019809:0.019809:0.019809:0.018477:0.018479:0.019809:0.019809:0.018479
從本公司的歷史經驗學習，培:@0.071429:0.850382:0.325069:0.850382:0.325069:0.836766:0.071429:0.836766:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.018479:0.019698:0.018479
養出發現和研發小分子藥的卓:@0.071429:0.873284:0.324958:0.873284:0.324958:0.859668:0.071429:0.859668:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.019588:0.018479
越能力。這些能力都有助於我:@0.071429:0.896186:0.325069:0.896186:0.325069:0.882570:0.071429:0.882570:0.019698:0.019698:0.018479:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.019698:0.018479
們在 開發平臺 出類拔 萃的成:@0.071429:0.919088:0.325060:0.919088:0.325060:0.905473:0.071429:0.905473:0.021380:0.018479:0.002892:0.021380:0.021380:0.021380:0.018479:0.002892:0.021380:0.021380:0.018479:0.002892:0.021380:0.021380:0.018479
德國比伯拉赫:@0.571904:0.178158:0.652539:0.178158:0.652539:0.168256:0.571904:0.168256:0.013439:0.013439:0.013439:0.013439:0.013439:0.013439
（BIBERACH）:@0.571904:0.190536:0.652539:0.190536:0.652539:0.180634:0.571904:0.180634:0.013439:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.013439
美國康乃狄格州 :@0.094761:0.201845:0.195554:0.201845:0.195554:0.191942:0.094761:0.191942:0.013439:0.013439:0.013439:0.013439:0.013439:0.013439:0.013439:0.006720
裡奇菲爾德（RIDGEFIELD）:@0.094761:0.215461:0.256031:0.215461:0.256031:0.205558:0.094761:0.205558:0.013439:0.013439:0.013439:0.013439:0.013439:0.013439:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.006720:0.013439
奧地利維也納:@0.584994:0.236761:0.665629:0.236761:0.665629:0.226859:0.584994:0.226859:0.013439:0.013439:0.013439:0.013439:0.013439:0.013439
日本神戶:@0.864757:0.246406:0.918513:0.246406:0.918513:0.236504:0.864757:0.236504:0.013439:0.013439:0.013439:0.013439
百靈佳殷格翰:@0.071429:0.313114:0.192381:0.313114:0.192381:0.298260:0.071429:0.298260:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159
主要的人類處方用藥:@0.071429:0.339108:0.252857:0.339108:0.252857:0.324255:0.071429:0.324255:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159
全球研發地點:@0.071429:0.365103:0.192381:0.365103:0.192381:0.350249:0.071429:0.350249:0.020159:0.020159:0.020159:0.020159:0.020159:0.020159
就。不過大分子藥也需要處理相:@0.357143:0.462752:0.618064:0.462752:0.618064:0.449136:0.357143:0.449136:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
當大範圍的治療目標，特別是近:@0.357143:0.485655:0.618064:0.485655:0.618064:0.472039:0.357143:0.472039:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018479
年來我們在蛋白質生物療法方面:@0.357143:0.508557:0.618008:0.508557:0.618008:0.494941:0.357143:0.494941:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
研發出最先進的功能，如今已在:@0.357143:0.531459:0.618064:0.531459:0.618064:0.517843:0.357143:0.517843:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018479
初步生產平臺交出約四分之一候:@0.357143:0.554361:0.618008:0.554361:0.618008:0.540745:0.357143:0.540745:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
選新藥。」伍德說。:@0.357143:0.577263:0.523452:0.577263:0.523452:0.563647:0.357143:0.563647:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
》時機成熟時，我們就會:@0.357143:0.621197:0.618174:0.621197:0.618174:0.603867:0.357143:0.603867:0.023777:0.023777:0.023777:0.023777:0.023777:0.023519:0.023777:0.023777:0.023777:0.023777:0.023519
全力投入《:@0.357143:0.651523:0.474735:0.651523:0.474735:0.634194:0.357143:0.634194:0.023519:0.023519:0.023519:0.023519:0.023519
    「開放式創新需要與外在世:@0.357143:0.690511:0.618119:0.690511:0.618119:0.676895:0.357143:0.676895:0.012288:0.012288:0.009239:0.003049:0.018701:0.018691:0.018691:0.018691:0.018691:0.018701:0.018691:0.018691:0.018691:0.018701:0.018691:0.018479
界積極進行雙向交流。」他解釋:@0.357143:0.714339:0.618082:0.714339:0.618082:0.700723:0.357143:0.700723:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018479:0.018479:0.018682:0.018682:0.018682:0.018479
說。「雖然我們必須對本公司創:@0.357143:0.737241:0.618082:0.737241:0.618082:0.723625:0.357143:0.723625:0.018479:0.018479:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018479
新的成果做適當的保護，但是仍:@0.357143:0.760143:0.618064:0.760143:0.618064:0.746527:0.357143:0.746527:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018479
有大量成果能夠和外界分享。」:@0.357143:0.783045:0.618082:0.783045:0.618082:0.769429:0.357143:0.769429:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018682:0.018479:0.018479:0.018479
伍德認為在更廣大的科學界進行:@0.357143:0.805947:0.618008:0.805947:0.618008:0.792331:0.357143:0.792331:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
外部交流和參與，對建立與擴大:@0.357143:0.828849:0.618064:0.828849:0.618064:0.815233:0.357143:0.815233:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
連結、以及加速通往未來契機的:@0.357143:0.851751:0.618062:0.851751:0.618062:0.838135:0.357143:0.838135:0.018664:0.018477:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
道路是必要的。所以他認為科學:@0.357143:0.874653:0.618064:0.874653:0.618064:0.861037:0.357143:0.861037:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
刊物對研究員之間的溝通來說至:@0.357143:0.897555:0.618008:0.897555:0.618008:0.883939:0.357143:0.883939:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018645:0.018479
為重要，並鼓勵百靈佳殷格翰的:@0.357143:0.921383:0.618064:0.921383:0.618064:0.907767:0.357143:0.907767:0.018664:0.018664:0.018479:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018664:0.018479
同仁盡量發表他們的研究發現。單:@0.642862:0.461898:0.928593:0.461898:0.928593:0.448282:0.642862:0.448282:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.018481:0.019135:0.018479
單是二○一六年，公司研究員就發:@0.642862:0.484800:0.928600:0.484800:0.928600:0.471184:0.642862:0.471184:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.018479:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
表了數百份科學報告，其中有許多:@0.642862:0.507703:0.928600:0.507703:0.928600:0.494087:0.642862:0.494087:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
都刊載在權威期刊。伍德對這樣多:@0.642862:0.530605:0.928600:0.530605:0.928600:0.516989:0.642862:0.516989:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.018479:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
的數量引以為豪，認為這是一個創:@0.642862:0.553507:0.928600:0.553507:0.928600:0.539891:0.642862:0.539891:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.018479:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
新的主要績效指標。招攬新生代傑:@0.642862:0.576409:0.928600:0.576409:0.928600:0.562793:0.642862:0.562793:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.018479:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
出科學家進入公司也是一大要事。:@0.642862:0.599311:0.928600:0.599311:0.928600:0.585695:0.642862:0.585695:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479:0.018479
「時下最優秀的年輕人都會去看一:@0.642862:0.622213:0.928582:0.622213:0.928582:0.608597:0.642862:0.608597:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.019089:0.018479
流期刊的出版物，瞭解有哪些地方:@0.642862:0.645115:0.928600:0.645115:0.928600:0.631499:0.642862:0.631499:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.018479:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
在從事重大的科學研究，把新藥帶:@0.642862:0.668017:0.928600:0.668017:0.928600:0.654401:0.642862:0.654401:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.018479:0.019135:0.019135:0.019135:0.019144:0.018479
給病人。」:@0.642862:0.690919:0.735256:0.690919:0.735256:0.677303:0.642862:0.677303:0.018479:0.018479:0.018479:0.018479:0.018479
   「無國界研究」可以作為下一波:@0.642862:0.713821:0.928576:0.713821:0.928576:0.700205:0.642862:0.700205:0.009239:0.009239:0.008886:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018124:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
創新浪潮的雷達：百靈佳殷格翰經:@0.642862:0.736723:0.928600:0.736723:0.928600:0.723107:0.642862:0.723107:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.018479:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
由與外部研究機構的合作，確保自:@0.642862:0.759626:0.928600:0.759626:0.928600:0.746010:0.642862:0.746010:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.019135:0.018479:0.019135:0.019135:0.019144:0.018479
己的科學家緊扣創新的脈動，不會:@0.642862:0.782528:0.928600:0.782528:0.928600:0.768912:0.642862:0.768912:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.018479:0.019135:0.019144:0.018479
錯過任何新出現的研究方法，並與:@0.642862:0.805430:0.928600:0.805430:0.928600:0.791814:0.642862:0.791814:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.018479:0.019135:0.019144:0.018479
最佳合作夥伴保持同步。與大學的:@0.642862:0.828332:0.928600:0.828332:0.928600:0.814716:0.642862:0.814716:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.019135:0.018479:0.019135:0.019135:0.019135:0.019144:0.018479
長期合作關係，例如日本京都大學:@0.642862:0.851234:0.928600:0.851234:0.928600:0.837618:0.642862:0.837618:0.019135:0.019135:0.019144:0.019135:0.019135:0.018479:0.019135:0.019135:0.019144:0.019135:0.019135:0.019135:0.019135:0.019144:0.018479
與美國哈佛大學（請參閱第 15 頁）:@0.642862:0.874136:0.928576:0.874136:0.928576:0.860520:0.642862:0.860520:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018126:0.018479:0.018479:0.018479:0.018479:0.018479:0.004442:0.009239:0.009239:0.004442:0.018479:0.018479
是「無國界研究」的核心。:@0.642862:0.897038:0.864608:0.897038:0.864608:0.883422:0.642862:0.883422:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479
    百靈佳殷格翰也積極建立公民:@0.642862:0.919940:0.928576:0.919940:0.928576:0.906324:0.642862:0.906324:0.011372:0.011374:0.011372:0.011372:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479:0.018479